Hub : Traits :

Overall health rating

459 significantly associated models · 122 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 74957325 75479163 1 1 1.1e-07 4.9e-06 4.9e-01 98 TYW3
2 1 117211384 118766534 1 1 7.9e-11 1.1e-09 7.8e-01 100 MAN1A2
3 1 155424065 156838141 1 1 2.1e-07 3.8e-07 1.0e+00 100 SEMA4A
4 1 201164764 202607593 2 1 2.3e-10 1.9e-10 1.0e+00 100 LMOD1
5 1 242590540 244345666 3 1 5.8e-11 1.8e-09 1.2e-01 93 SDCCAG8
6 2 64586858 66006558 1 1 6.7e-08 1.3e-06 3.8e-01 97 CEP68
7 2 108372251 110002052 2 1 2.9e-08 2.4e-08 2.2e-01 95 GCC2
8 2 197745121 200117777 3 1 1.3e-09 1.4e-09 1.0e+00 100 MARS2
9 2 207107801 208531683 1 1 1.8e-08 3.8e-08 1.0e+00 100 CPO
10 3 48381826 51077419 27 1 3.5e-17 1.7e-14 5.5e-01 99 RNF123
11 3 70757099 71880670 1 1 2.5e-07 1.8e-07 1.0e+00 100 FOXP1
12 3 135861666 137253713 1 1 2.4e-07 2.5e-06 1.6e-01 91 RP11-731C17.2
13 4 1785025 3943984 9 7 3.3e-14 3.3e-13 1.0e+00 100 C4orf10 GRK4 RNF4
14 4 89947254 91439574 1 1 1.4e-07 5.1e-08 2.1e-02 82 SNCA
15 4 158997448 160525502 1 1 3.7e-08 3.7e-09 1.0e+00 100 FNIP2
16 6 33857525 35542476 2 1 4.4e-08 1.9e-08 1.7e-01 94 C6orf106
17 7 1161158 2972072 1 1 2.8e-10 8.4e-12 4.5e-05 64 MAD1L1
18 8 8165004 10985432 3 2 7.7e-09 3.5e-10 2.6e-03 77 MSRA RP11-375N15.2
19 8 11276542 13120332 1 1 2.2e-07 1.2e-08 4.4e-03 75 LOC100506990
20 8 29996824 31433801 1 1 8.1e-12 7.2e-12 4.0e-03 82 TEX15
21 8 142629143 144179460 1 1 1.7e-10 1.1e-06 3.1e-01 96 TSNARE1
22 9 13891813 15288045 1 1 1.7e-07 2.0e-07 6.5e-02 87 RP11-408A13.4
23 9 95502571 96898436 2 2 1.7e-07 3.6e-08 3.5e-03 72 PHF2 RP11-165J3.6
24 9 126927285 129422783 6 8 1.4e-12 1.2e-12 1.0e+00 100 GOLGA1 PBX3 WDR38
25 10 98926838 100488720 1 1 1.7e-08 4.9e-07 6.9e-02 87 CRTAC1
26 11 64501991 67059499 13 2 1.1e-10 1.0e-07 3.7e-02 85 CTD-3074O7.5 SNX32
27 11 76827992 78216992 1 1 9.7e-08 3.3e-06 4.6e-01 97 AP000580.1
28 11 112486568 113952419 3 1 7.0e-10 5.6e-09 2.3e-01 96 ANKK1
29 12 55746910 57125879 1 1 2.8e-07 7.8e-06 2.6e-02 75 RPS26
30 13 31078511 32595740 1 1 3.1e-08 2.6e-08 2.3e-01 95 B3GALTL
31 14 69027866 70518587 3 1 5.1e-09 3.4e-09 5.2e-02 89 DCAF5
32 15 73524629 74968873 2 2 1.9e-08 3.8e-06 3.6e-02 80 LOXL1-AS1 STOML1
33 16 24614505 25167985 1 1 2.4e-07 2.7e-10 7.3e-05 61 SLC5A11
34 16 29972690 31833122 9 1 3.5e-10 7.9e-11 2.5e-02 88 KAT8
35 16 52772129 54210447 1 1 1.4e-07 2.7e-07 1.3e-07 -5 RBL2
36 16 71070698 72569466 3 1 3.0e-08 8.7e-08 5.5e-01 99 PHLPP2
37 17 1594359 2985816 1 1 1.2e-07 2.5e-07 5.4e-01 99 RP1-59D14.1
38 17 42892795 43383100 1 1 1.1e-07 1.5e-07 3.3e-02 84 NMT1
39 17 47119135 47685050 1 1 1.0e-08 3.5e-10 1.0e-02 83 ZNF652
40 17 65289798 66844411 4 1 7.6e-09 7.7e-09 5.1e-02 89 LINC00674
41 19 1226004 2732986 2 1 2.0e-08 3.6e-09 1.3e-02 82 BTBD2
42 19 18359524 19753882 1 1 2.9e-07 1.1e-05 9.1e-06 -2 AC005932.1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Depressed Affect (Nagel 2018) 2.94 4 3 6.7 0.99 1.0e-02 ANKK1 DCAF5 RNF123 RP11-165J3.6
Depression (Nagel 2018) 2.97 4 0 0.0 0.99 9.2e-03 ANKK1 DCAF5 PHLPP2 RP11-165J3.6
Intelligence (Savage-Jansen 2018) 3.22 10 7 15.6 -0.97 5.0e-06 FOXP1 LMOD1 PHLPP2 RBL2 RNF123 RP11-731C17.2 SLC5A11 TEX15 TSNARE1 TYW3
Neuroticism (Nagel 2018) 2.78 6 2 4.4 0.95 4.3e-03 ANKK1 DCAF5 RNF123 RP11-165J3.6 RP1-59D14.1 TSNARE1
Schizophrenia (2018) 1.43 2 0 0.0 0.00 1.0e+00 FOXP1 MARS2
Schizophrenia vs Biploar Disorder 2.30 1 0 0.0 0.00 1.0e+00 LMOD1
Worry (Nagel 2018) 1.96 4 2 4.4 0.57 4.3e-01 ANKK1 KAT8 RP11-165J3.6 TSNARE1
Alzheimer’s Disease (in mother) 1.20 1 0 0.0 0.00 1.0e+00 KAT8
Alzheimer’s Disease (including proxy) 1.09 1 1 2.2 0.00 1.0e+00 KAT8
Crohns Disease (2017) 1.30 3 0 0.0 0.00 1.0e+00 MARS2 RNF123 SNX32
Irritable Bowel Disease (IBD) 1.33 1 1 2.2 0.00 1.0e+00 RNF123
Ulcerative Colitis (UC) 1.42 1 1 2.2 0.00 1.0e+00 RNF123
Major Depression (MDD) 2.43 1 0 0.0 0.00 1.0e+00 CPO
Reaction Time 1.39 1 0 0.0 0.00 1.0e+00 SDCCAG8
Verbal and Numeric Reasoning (VNR) 2.92 7 3 6.7 -0.95 1.2e-03 FOXP1 PHLPP2 RBL2 RNF123 RP11-731C17.2 SLC5A11 TEX15
Breast Cancer 1.15 3 0 0.0 0.00 1.0e+00 CTD-3074O7.5 SEMA4A SNX32
Prostate Cancer 1.16 1 0 0.0 0.00 1.0e+00 RNF123
Age at First Birth 3.42 1 1 2.2 0.00 1.0e+00 RNF123
Body Mass Index (BMI) (2010) 1.65 1 0 0.0 0.00 1.0e+00 LMOD1
Coronary Artery Disease (CAD) 1.84 1 0 0.0 0.00 1.0e+00 LMOD1
Crohns Disease (2012) 1.56 2 0 0.0 0.00 1.0e+00 MARS2 RNF123
HDL Cholesterol 1.69 2 1 2.2 0.00 1.0e+00 C6orf106 CEP68
LDL Cholesterol 1.41 1 0 0.0 0.00 1.0e+00 C6orf106
Neuroticism (2016) 2.87 5 1 2.2 -0.46 4.3e-01 ANKK1 CPO LOC100506990 MSRA RP1-59D14.1
Rheumatoid Arthritis 1.20 1 0 0.0 0.00 1.0e+00 RPS26
Schizophrenia (2014) 1.74 1 0 0.0 0.00 1.0e+00 MARS2
Triglycerides 2.09 3 1 2.2 0.00 1.0e+00 KAT8 LOC100506990 ZNF652
Ulcerative Colitis 1.41 1 0 0.0 0.00 1.0e+00 RNF123
Blood Eosinophil Count 1.22 5 3 6.7 0.43 4.6e-01 LINC00674 NMT1 RPS26 SNX32 ZNF652
Blood Platelet Count 1.22 11 7 15.6 0.43 1.1e-01 AP000580.1 C4orf10 C6orf106 GCC2 GRK4 MARS2 NMT1 PBX3 RP1-59D14.1 SEMA4A SNX32
Blood Red Count 0.87 10 5 11.1 0.58 2.9e-02 C6orf106 CTD-3074O7.5 DCAF5 KAT8 MARS2 PBX3 PHF2 RP1-59D14.1 RPS26 SEMA4A
Blood White Count 1.54 10 5 11.1 0.73 3.2e-03 C4orf10 C6orf106 GRK4 KAT8 PBX3 RNF123 SDCCAG8 SLC5A11 TEX15 ZNF652
Heel T-Score 0.73 9 3 6.7 0.21 5.8e-01 AP000580.1 CTD-3074O7.5 KAT8 LINC00674 NMT1 PHF2 RP11-375N15.2 SLC5A11 SNX32
BMI 4.19 25 15 33.3 0.93 4.3e-13 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FNIP2 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MAN1A2 MARS2 PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 SDCCAG8 SLC5A11 SNX32 STOML1 TEX15
Height 2.14 16 14 31.1 -0.32 1.6e-01 AP000580.1 C6orf106 GCC2 GRK4 LINC00674 LOXL1-AS1 NMT1 PBX3 PHLPP2 RBL2 RP11-165J3.6 RP11-731C17.2 SLC5A11 SNX32 STOML1 ZNF652
Waist Hip Ratio (WHR) 1.59 6 2 4.4 0.35 5.0e-01 C6orf106 GRK4 MARS2 PBX3 RBL2 WDR38
Systolic Blood Pressure 2.60 10 6 13.3 0.09 7.4e-01 CEP68 LINC00674 NMT1 PBX3 PHLPP2 RNF123 SLC5A11 SNX32 TSNARE1 ZNF652
Smoking Status 3.99 9 1 2.2 0.98 3.8e-10 C6orf106 FOXP1 GRK4 PBX3 RNF123 SLC5A11 SNX32 WDR38 ZNF652
Allergy or Eczema 1.81 6 3 6.7 -0.05 9.2e-01 AP000580.1 C6orf106 MARS2 NMT1 RPS26 ZNF652
Cardiovascular Disease 3.31 13 5 11.1 0.96 1.2e-09 ANKK1 C4orf10 CEP68 GRK4 KAT8 LMOD1 MAD1L1 NMT1 RBL2 RPS26 SNX32 TEX15 ZNF652
Respiratory disease 2.57 3 1 2.2 0.00 1.0e+00 NMT1 RNF123 ZNF652
Type 2 Diabetes (T2D) (2018) 2.37 5 0 0.0 -0.37 5.4e-01 KAT8 LINC00674 RBL2 RNF123 SNX32
Lung FEV1/FVC ratio 1.51 7 4 8.9 0.42 3.5e-01 C6orf106 LINC00674 LMOD1 LOXL1-AS1 PHF2 SLC5A11 ZNF652
Lung FVC 1.56 8 5 11.1 0.22 5.0e-01 C4orf10 C6orf106 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 RNF123
Neuroticism 2.79 7 3 6.7 0.80 3.0e-02 ANKK1 DCAF5 KAT8 RNF123 RP11-165J3.6 RP1-59D14.1 TSNARE1
Chronotype (morning person) 1.46 2 1 2.2 0.00 1.0e+00 LMOD1 MARS2
Hair Pigment 0.10 1 0 0.0 0.00 1.0e+00 LINC00674
Tanning 0.33 2 0 0.0 0.00 1.0e+00 PBX3 SDCCAG8
Hand grip strength (left) 2.56 7 2 4.4 -0.79 1.9e-02 AP000580.1 FOXP1 GOLGA1 LOXL1-AS1 NMT1 PBX3 SLC5A11
Number of treatments/medications taken 4.22 5 1 2.2 1.00 6.0e-05 FOXP1 LINC00674 RNF123 SDCCAG8 ZNF652
Sensitivity / hurt feelings 2.62 4 2 4.4 0.99 7.9e-03 ANKK1 DCAF5 PBX3 RP11-165J3.6
Frequency of depressed mood in last 2 weeks 2.56 2 0 0.0 0.00 1.0e+00 ANKK1 RP11-165J3.6
Hearing difficulty/problems: Yes 1.92 1 0 0.0 0.00 1.0e+00 CPO
Relative age of first facial hair 1.43 1 0 0.0 0.00 1.0e+00 C6orf106
Other serious medical condition/disability diagnosed by doctor 2.78 1 0 0.0 0.00 1.0e+00 ANKK1
Systolic blood pressure, automated reading 3.09 8 5 11.1 0.92 1.2e-03 CEP68 LOC100506990 MSRA NMT1 RNF123 SLC5A11 SNX32 TSNARE1
Angina 2.53 2 0 0.0 0.00 1.0e+00 CPO ZNF652
Medication: Co-codamol 3.29 1 0 0.0 0.00 1.0e+00 RNF123
Medication: Metformin 2.16 1 0 0.0 0.00 1.0e+00 MAD1L1
Pack years adult smoking proportion 3.17 2 0 0.0 1.00 2.2e-03 GRK4 RP1-59D14.1
Impedance of leg (right) 2.82 15 10 22.2 -0.55 3.4e-02 C6orf106 CPO KAT8 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 RBL2 RNF123 RP11-731C17.2 RP1-59D14.1 SNX32 ZNF652
Leg fat-free mass (left) 3.05 17 8 17.8 0.53 2.9e-02 BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Trunk fat percentage 4.23 19 12 26.7 0.88 6.3e-08 AC005932.1 ANKK1 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15 ZNF652
Hand grip strength (right) 2.72 8 4 8.9 -0.61 6.3e-02 AP000580.1 C6orf106 GOLGA1 LOXL1-AS1 NMT1 PBX3 RBL2 SLC5A11
Current tobacco smoking 4.50 5 0 0.0 0.99 9.4e-08 FNIP2 MSRA PBX3 SLC5A11 WDR38
Average weekly fortified wine intake 1.95 1 0 0.0 0.00 1.0e+00 SLC5A11
Maternal smoking around birth 2.71 1 1 2.2 0.00 1.0e+00 SLC5A11
Fed-up feelings 2.94 5 1 2.2 0.99 1.3e-03 ANKK1 DCAF5 RNF123 SLC5A11 TEX15
Frequency of unenthusiasm / disinterest in last 2 weeks 4.38 3 0 0.0 0.00 1.0e+00 ANKK1 DCAF5 RP11-165J3.6
Taking other prescription medications 3.81 3 2 4.4 0.00 1.0e+00 LINC00674 RNF123 ZNF652
Age when periods started (menarche) 2.18 4 1 2.2 -0.31 6.9e-01 RNF123 RNF4 RPS26 SNX32
Heel bone mineral density (BMD) T-score, automated (left) 1.49 2 2 4.4 0.00 1.0e+00 LOC100506990 MSRA
Qualifications: CSEs or equivalent 1.83 2 0 0.0 0.00 1.0e+00 FNIP2 RNF123
High blood pressure 3.63 14 4 8.9 0.97 7.7e-09 CEP68 KAT8 LMOD1 LOC100506990 MSRA NMT1 RBL2 RP11-375N15.2 RPS26 SLC5A11 SNX32 TEX15 TSNARE1 ZNF652
Hayfever, allergic rhinitis or eczema 1.75 4 2 4.4 -0.56 4.4e-01 C6orf106 MARS2 RPS26 ZNF652
Stomach or abdominal pain in last month 2.53 1 0 0.0 0.00 1.0e+00 RP11-165J3.6
Supplements: Glucosamine 2.10 1 0 0.0 0.00 1.0e+00 NMT1
Medication: Levothyroxine sodium 1.29 1 0 0.0 0.00 1.0e+00 MSRA
Sitting height 1.69 7 7 15.6 -0.54 8.5e-02 C6orf106 GRK4 LOXL1-AS1 NMT1 PBX3 RBL2 ZNF652
Body mass index (BMI) 5.63 25 19 42.2 0.95 1.1e-15 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA PHF2 RNF123 RP11-375N15.2 RP11-408A13.4 RP11-731C17.2 SDCCAG8 SLC5A11 SNCA SNX32 STOML1 TEX15
Impedance of leg (left) 2.80 17 10 22.2 -0.53 2.9e-02 C6orf106 CPO CRTAC1 KAT8 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 RBL2 RNF123 RP11-731C17.2 RP1-59D14.1 SNX32 WDR38 ZNF652
Leg predicted mass (left) 3.04 18 8 17.8 0.53 2.2e-02 BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32 WDR38
Trunk fat mass 4.40 19 10 22.2 0.91 6.3e-09 AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MSRA RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Waist circumference 4.87 19 12 26.7 0.94 4.9e-11 AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 PHF2 RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Number of incorrect matches in round 1.51 1 1 2.2 0.00 1.0e+00 KAT8
Alcohol usually taken with meals 3.84 5 2 4.4 -0.97 7.5e-03 FOXP1 LMOD1 RP1-59D14.1 TSNARE1 ZNF652
Nervous feelings 2.58 5 1 2.2 -0.18 7.7e-01 ANKK1 KAT8 LOC100506990 MSRA TSNARE1
Frequency of tenseness / restlessness in last 2 weeks 2.81 6 0 0.0 0.99 8.2e-05 ANKK1 B3GALTL CPO RNF123 RP11-165J3.6 TYW3
Hearing difficulty/problems with background noise 1.52 1 0 0.0 0.00 1.0e+00 CPO
Forced vital capacity (FVC) 2.25 11 3 6.7 -0.77 1.2e-03 AP000580.1 C6orf106 CTD-3074O7.5 FOXP1 GOLGA1 GRK4 KAT8 LOC100506990 LOXL1-AS1 RBL2 RNF123
Heel bone mineral density (BMD) T-score, automated (right) 1.43 3 2 4.4 0.00 1.0e+00 LOC100506990 MSRA SLC5A11
Ever unenthusiastic/disinterested for a whole week 1.76 1 0 0.0 0.00 1.0e+00 RNF123
Qualifications: None of the above 5.07 13 6 13.3 0.98 2.0e-11 B3GALTL C4orf10 FOXP1 GOLGA1 GRK4 PHLPP2 RBL2 RNF123 RPS26 SDCCAG8 SLC5A11 TEX15 TSNARE1
Financial difficulties in last 2 years 3.66 2 0 0.0 0.00 1.0e+00 KAT8 PBX3
Mouth/teeth dental problems 2.74 1 0 0.0 0.00 1.0e+00 SDCCAG8
Heart attack 2.50 1 0 0.0 0.00 1.0e+00 ZNF652
Allergy 1.95 6 2 4.4 -0.12 8.1e-01 AP000580.1 C6orf106 MARS2 NMT1 RPS26 ZNF652
Diabetes (self-reported) 2.09 2 0 0.0 0.00 1.0e+00 RBL2 RNF123
Hayfever/allergic rhinitis (self-reported) 1.45 1 0 0.0 0.00 1.0e+00 MARS2
Fluid intelligence score 2.89 8 3 6.7 -0.97 6.0e-05 FOXP1 LMOD1 PHLPP2 RBL2 RNF123 SLC5A11 TEX15 TYW3
Illnesses of siblings 3.08 3 1 2.2 0.00 1.0e+00 KAT8 RBL2 SLC5A11
Neuroticism score 3.32 7 5 11.1 0.42 3.5e-01 ANKK1 DCAF5 LOC100506990 MSRA RNF123 RP11-165J3.6 RP1-59D14.1
Weight 4.16 20 9 20.0 0.82 8.5e-06 ANKK1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA PHLPP2 RBL2 RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Impedance of arm (right) 3.20 15 8 17.8 -0.96 3.0e-08 C6orf106 FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 SNX32 STOML1 ZNF652
Arm fat percentage (right) 4.65 20 15 33.3 0.97 1.5e-14 AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Trunk fat-free mass 2.61 11 9 20.0 0.34 3.1e-01 C6orf106 CPO KAT8 LMOD1 MARS2 NMT1 PHLPP2 RBL2 RNF123 SLC5A11 WDR38
Hip circumference 3.68 16 7 15.6 0.79 3.0e-04 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RBL2 RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Alcohol intake versus 10 years previously 1.73 1 0 0.0 0.00 1.0e+00 RNF123
Father's age at death 2.50 1 0 0.0 0.00 1.0e+00 LOC100506990
Worrier / anxious feelings 2.72 3 2 4.4 0.00 1.0e+00 LOC100506990 MSRA RP11-731C17.2
Frequency of tiredness / lethargy in last 2 weeks 5.65 10 3 6.7 0.99 6.0e-08 ANKK1 CPO DCAF5 LMOD1 RNF4 RP11-165J3.6 RP11-731C17.2 RP1-59D14.1 STOML1 TYW3
Number of live births 1.61 2 0 0.0 0.00 1.0e+00 MAN1A2 RP11-408A13.4
Forced expiratory volume in 1-second (FEV1) 2.69 12 3 6.7 -0.82 1.9e-04 AP000580.1 C6orf106 CTD-3074O7.5 FOXP1 GOLGA1 GRK4 KAT8 LOC100506990 MSRA PBX3 RNF123 WDR38
Pulse rate 1.97 2 0 0.0 0.00 1.0e+00 FNIP2 RBL2
Noisy workplace 2.67 1 0 0.0 0.00 1.0e+00 B3GALTL
Qualifications: A levels/AS levels or equivalent 3.39 8 2 4.4 -0.93 9.5e-04 FOXP1 GRK4 RBL2 RNF123 SDCCAG8 SLC5A11 TEX15 TSNARE1
Mouth/teeth dental problems: Dentures 3.69 3 0 0.0 0.99 8.6e-03 PBX3 RNF123 RP11-731C17.2
Asthma 2.09 2 1 2.2 0.00 1.0e+00 NMT1 ZNF652
Medication: Cholesterol lowering 2.13 1 0 0.0 0.00 1.0e+00 KAT8
Forced expiratory volume in 1-second (FEV1), Best measure 2.43 10 1 2.2 -0.77 3.3e-03 AP000580.1 C4orf10 C6orf106 FOXP1 GRK4 KAT8 LOC100506990 MSRA PBX3 RNF123
Impedance of arm (left) 3.14 14 9 20.0 -0.96 8.5e-08 C6orf106 FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA PHF2 RNF123 RP11-731C17.2 RPS26 SNX32 STOML1 ZNF652
Arm fat mass (right) 4.97 20 12 26.7 0.93 4.0e-11 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Trunk predicted mass 2.61 11 9 20.0 0.34 3.1e-01 C6orf106 CPO KAT8 LMOD1 MARS2 NMT1 PHLPP2 RBL2 RNF123 SLC5A11 WDR38
Standing height 2.53 18 14 31.1 -0.54 3.5e-03 AP000580.1 C4orf10 C6orf106 GRK4 LINC00674 LOC100506990 LOXL1-AS1 MSRA NMT1 PBX3 PHLPP2 RBL2 RP11-165J3.6 RP11-731C17.2 SLC5A11 SNX32 STOML1 ZNF652
Exposure to tobacco smoke at home 1.85 1 1 2.2 0.00 1.0e+00 RNF123
Tense / 'highly strung' 2.36 4 1 2.2 0.29 7.1e-01 ANKK1 KAT8 LOC100506990 RP11-165J3.6
Seen doctor (GP) for nerves, anxiety, tension or depression 2.35 3 0 0.0 0.00 1.0e+00 ANKK1 B3GALTL CTD-3074O7.5
Birth weight of first child 1.49 1 0 0.0 0.00 1.0e+00 RBL2
Peak expiratory flow (PEF) 2.31 5 1 2.2 -1.00 6.2e-05 AP000580.1 GOLGA1 LOC100506990 MSRA RP11-375N15.2
Pulse wave reflection index 1.87 1 0 0.0 0.00 1.0e+00 PBX3
Ever highly irritable/argumentative for 2 days 1.93 1 0 0.0 0.00 1.0e+00 RNF123
Qualifications: O levels/GCSEs or equivalent 3.24 3 0 0.0 0.00 1.0e+00 GRK4 RNF123 TSNARE1
Medication: Paracetamol 2.62 2 1 2.2 0.00 1.0e+00 RNF123 SDCCAG8
Medication for cholesterol, blood pressure or diabetes 2.47 1 0 0.0 0.00 1.0e+00 ZNF652
Hypothyroidism/myxoedema (self-reported) 1.27 1 0 0.0 0.00 1.0e+00 MSRA
Medication: Ventolin 100micrograms inhaler 1.82 1 0 0.0 0.00 1.0e+00 ZNF652
Birth weight 1.33 1 0 0.0 0.00 1.0e+00 GCC2
Chronic bronchitis/emphysema (mother) 1.66 1 0 0.0 0.00 1.0e+00 RNF123
High blood pressure (siblings) 2.53 2 0 0.0 0.00 1.0e+00 KAT8 SLC5A11
Forced vital capacity (FVC), Best measure 2.06 8 1 2.2 -0.93 8.8e-05 AP000580.1 C4orf10 FOXP1 GRK4 KAT8 LOXL1-AS1 RBL2 RNF123
Body fat percentage 4.78 20 13 28.9 0.96 2.9e-13 AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MSRA RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15
Leg fat percentage (right) 5.15 22 11 24.4 0.96 4.6e-15 ANKK1 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 DCAF5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MSRA NMT1 PHF2 RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNCA SNX32 TEX15
Arm fat-free mass (right) 3.08 13 10 22.2 0.50 8.4e-02 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Exposure to tobacco smoke outside home 3.10 4 1 2.2 0.97 3.3e-02 FNIP2 MARS2 RNF123 SDCCAG8
Comparative body size at age 10 1.76 6 2 4.4 0.72 1.1e-01 LOC100506990 MARS2 MSRA RP11-165J3.6 SNX32 ZNF652
Worry too long after embarrassment 2.38 4 2 4.4 -0.20 8.0e-01 ANKK1 LOC100506990 MSRA RP1-59D14.1
Wheeze or whistling in the chest in last year 4.15 7 1 2.2 1.00 8.3e-07 B3GALTL KAT8 LINC00674 LMOD1 NMT1 RNF123 ZNF652
Reason for reducing amount of alcohol drunk: Health precaution 2.08 1 0 0.0 0.00 1.0e+00 RPS26
Age at first live birth 4.87 7 1 2.2 -0.99 5.1e-06 GRK4 PHLPP2 RNF123 RNF4 RP11-408A13.4 STOML1 TYW3
Health satisfaction 5.97 8 1 2.2 0.99 4.1e-06 ANKK1 C6orf106 CTD-3074O7.5 GRK4 LINC00674 LMOD1 RNF123 TSNARE1
Shortness of breath walking on level ground 2.94 2 0 0.0 0.00 1.0e+00 LMOD1 PHLPP2
Qualifications: College or University degree 5.43 15 10 22.2 -0.98 6.4e-13 B3GALTL C4orf10 DCAF5 FNIP2 FOXP1 GRK4 LMOD1 RBL2 RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15 TSNARE1
Eye problems/disorders: None of the above 0.96 1 0 0.0 0.00 1.0e+00 NMT1
Emphysema/chronic bronchitis 2.45 1 0 0.0 0.00 1.0e+00 RP11-375N15.2
Medication for pain relief, constipation, heartburn 3.68 6 0 0.0 -0.99 1.2e-04 C6orf106 CPO LMOD1 RP11-165J3.6 SDCCAG8 TEX15
Neck or shoulder pain in last month 3.21 2 0 0.0 0.00 1.0e+00 PHLPP2 SNX32
Medication: Blood pressure 2.37 3 1 2.2 0.00 1.0e+00 MSRA SNX32 ZNF652
Angina (self-reported) 2.41 1 0 0.0 0.00 1.0e+00 ZNF652
Medication: Omeprazole 2.56 1 0 0.0 0.00 1.0e+00 C6orf106
Medication: Seretide 50 evohaler 2.09 2 0 0.0 0.00 1.0e+00 RNF123 ZNF652
Whole body fat mass 4.88 21 11 24.4 0.93 9.1e-11 AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Leg fat mass (right) 5.29 22 12 26.7 0.93 2.3e-11 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA PHF2 RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNCA SNX32 TEX15
Arm predicted mass (right) 3.11 15 9 20.0 0.55 3.2e-02 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Pulse rate, automated reading 2.78 7 5 11.1 -0.15 6.7e-01 C6orf106 FNIP2 LMOD1 PBX3 RBL2 RP1-59D14.1 SLC5A11
Alcohol intake frequency. 3.36 9 2 4.4 0.94 2.0e-04 CRTAC1 CTD-3074O7.5 DCAF5 FOXP1 KAT8 RNF123 RNF4 TEX15 TSNARE1
Comparative height size at age 10 1.68 9 4 8.9 -0.17 6.1e-01 ANKK1 C6orf106 LINC00674 LOXL1-AS1 PBX3 PHLPP2 RBL2 RP11-731C17.2 STOML1
Suffer from 'nerves' 1.48 2 0 0.0 0.00 1.0e+00 ANKK1 LOC100506990
Chest pain or discomfort 3.80 3 0 0.0 0.99 8.2e-04 CPO GRK4 MAN1A2
Age at last live birth 3.85 2 1 2.2 0.00 1.0e+00 LINC00674 RNF123
Leg pain on walking 2.77 1 0 0.0 0.00 1.0e+00 RNF123
Medication: Aspirin 2.12 2 0 0.0 0.00 1.0e+00 CPO LMOD1
Knee pain experienced in last month 3.35 3 0 0.0 0.00 1.0e+00 KAT8 PHLPP2 SDCCAG8
Hypertension (Self-reported) 3.72 14 5 11.1 0.97 3.9e-09 CEP68 KAT8 LMOD1 LOC100506990 MSRA NMT1 RBL2 RP11-375N15.2 RPS26 SLC5A11 SNX32 TEX15 TSNARE1 ZNF652
Forced expiratory volume in 1-second (FEV1), predicted 1.34 1 1 2.2 0.00 1.0e+00 C6orf106
Whole body fat-free mass 2.83 14 9 20.0 0.43 1.3e-01 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Leg fat-free mass (right) 2.94 15 8 17.8 0.47 8.0e-02 BTBD2 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Arm fat percentage (left) 4.75 19 15 33.3 0.97 5.5e-14 AC005932.1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Average weekly red wine intake 3.00 5 1 2.2 -0.99 1.6e-03 CTD-3074O7.5 FNIP2 FOXP1 RP1-59D14.1 SLC5A11
Mood swings 3.37 5 2 4.4 0.99 5.4e-04 ANKK1 AP000580.1 RNF123 RP11-165J3.6 SLC5A11
Loneliness, isolation 3.12 2 0 0.0 0.00 1.0e+00 LINC00674 RP11-165J3.6
Long-standing illness, disability or infirmity 5.02 5 0 0.0 1.00 2.3e-07 ANKK1 CTD-3074O7.5 NMT1 PBX3 ZNF652
Diabetes diagnosed by doctor 2.17 1 0 0.0 0.00 1.0e+00 RBL2
Qualifications: nursing, teaching 2.67 3 1 2.2 0.00 1.0e+00 LMOD1 RNF123 SDCCAG8
Medication for cholesterol 2.51 1 0 0.0 0.00 1.0e+00 RBL2
Back pain experienced in last month 3.36 3 0 0.0 0.00 1.0e+00 C6orf106 FNIP2 RPS26
Mineral and other dietary supplements 2.95 2 0 0.0 0.75 2.5e-01 GRK4 NMT1
Asthma (self-reported) 2.13 1 1 2.2 0.00 1.0e+00 ZNF652
Osteoarthritis (self-reported) 3.40 3 0 0.0 0.00 1.0e+00 NMT1 PBX3 RP11-165J3.6
Medication: Aspirin 2.02 1 0 0.0 0.00 1.0e+00 LMOD1
Smoking status: Current 4.21 5 0 0.0 0.98 1.1e-06 FNIP2 GOLGA1 PBX3 SLC5A11 WDR38
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.03 2 1 2.2 0.00 1.0e+00 KAT8 RNF123
Whole body water mass 2.83 14 9 20.0 0.43 1.3e-01 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Leg predicted mass (right) 2.92 16 8 17.8 0.49 5.4e-02 BTBD2 C6orf106 CPO KAT8 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Arm fat mass (left) 4.99 20 13 28.9 0.93 1.1e-10 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Number of self-reported non-cancer illnesses 4.44 4 1 2.2 0.99 1.3e-02 CEP68 GRK4 MAN1A2 ZNF652
Miserableness 2.97 6 3 6.7 0.76 7.8e-02 ANKK1 LOC100506990 RNF123 RP11-165J3.6 SDCCAG8 SLC5A11
Guilty feelings 2.49 4 1 2.2 0.20 8.0e-01 ANKK1 LOC100506990 MSRA RNF123
Financial situation satisfaction 2.53 1 0 0.0 0.00 1.0e+00 RNF123
Eye problems/disorders: Glaucoma 1.75 1 0 0.0 0.00 1.0e+00 TEX15
Medication: Blood pressure 2.62 3 1 2.2 0.00 1.0e+00 LOC100506990 MSRA NMT1
Pain type(s) experienced in last month: Hip pain 3.52 1 0 0.0 0.00 1.0e+00 CRTAC1
Supplements: Fish oil (including cod liver oil) 3.12 1 0 0.0 0.40 6.0e-01 GRK4
High cholesterol (Self-reported) 1.56 1 0 0.0 0.00 1.0e+00 RP11-375N15.2
Medication: Bendroflumethiazide 2.24 2 1 2.2 0.00 1.0e+00 LOC100506990 TEX15
Medication: Paracetamol 2.44 3 1 2.2 0.00 1.0e+00 NMT1 RNF123 SDCCAG8
Basal metabolic rate 3.14 17 9 20.0 0.52 3.3e-02 BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32 WDR38
Leg fat percentage (left) 5.30 24 13 28.9 0.96 2.2e-16 ANKK1 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 DCAF5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA NMT1 PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15
Arm fat-free mass (left) 3.18 15 9 20.0 0.56 3.0e-02 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Number of operations (self-reported) 2.14 1 0 0.0 0.00 1.0e+00 RNF123
Average weekly beer plus cider intake 2.56 2 1 2.2 0.00 1.0e+00 NMT1 RNF123
Irritability 2.43 2 2 4.4 0.00 1.0e+00 LOC100506990 MSRA
Diastolic blood pressure, automated reading 3.35 13 10 22.2 0.85 2.2e-04 AP000580.1 KAT8 LMOD1 LOC100506990 MSRA NMT1 PBX3 RNF123 SDCCAG8 SLC5A11 SNX32 TSNARE1 ZNF652
Unable to work because of sickness or disability 5.67 4 0 0.0 0.99 1.1e-04 GRK4 LOXL1-AS1 PBX3 SLC5A11
Commuting to job workplace: Cycle 2.40 1 0 0.0 0.00 1.0e+00 RP1-59D14.1
Vascular/heart problems diagnosed by doctor 3.92 16 5 11.1 -0.98 9.4e-11 C4orf10 CEP68 GRK4 KAT8 LMOD1 LOC100506990 MSRA NMT1 RBL2 RP11-375N15.2 RPS26 SLC5A11 SNX32 TEX15 TSNARE1 ZNF652
Cholesterol lowering medication 1.77 2 0 0.0 0.00 1.0e+00 CTD-3074O7.5 KAT8
Pain experienced in last month 5.03 8 2 4.4 -0.99 2.3e-06 CPO GOLGA1 MAN1A2 PHLPP2 RNF123 RP11-165J3.6 RP11-731C17.2 TYW3
Heart attack/myocardial infarction (self-reported) 2.46 1 0 0.0 0.00 1.0e+00 ZNF652
Pack years of smoking 2.76 2 0 0.0 0.00 1.0e+00 GRK4 RP1-59D14.1
Impedance of whole body 3.16 16 9 20.0 -0.66 5.6e-03 C6orf106 CPO FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 RBL2 RNF123 RP11-731C17.2 RP1-59D14.1 SNX32 STOML1 ZNF652
Leg fat mass (left) 5.36 23 12 26.7 0.92 5.8e-12 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 SDCCAG8 SLC5A11 SNCA SNX32 TEX15
Arm predicted mass (left) 3.22 16 9 20.0 0.60 1.5e-02 C6orf106 CPO FNIP2 KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 12 0.344 2.2
GTEx Adipose Visceral Omentum 5 0.246 2.2
GTEx Adrenal Gland 4 0.275 2.1
GTEx Artery Aorta 7 0.235 2.2
GTEx Artery Coronary 4 0.338 2.2
GTEx Artery Tibial 8 0.213 2.2
GTEx Brain Caudate basal ganglia 2 0.217 2.2
GTEx Brain Cerebellar Hemisphere 6 0.403 2.1
GTEx Brain Cerebellum 9 0.454 2.3
GTEx Brain Cortex 5 0.483 2.4
GTEx Brain Frontal Cortex BA9 4 0.433 2.3
GTEx Brain Hippocampus 0 0.000 1.9
GTEx Brain Hypothalamus 1 0.169 1.9
GTEx Brain Nucleus accumbens basal ganglia 3 0.347 2.0
GTEx Brain Putamen basal ganglia 1 0.160 2.1
GTEx Breast Mammary Tissue 6 0.304 2.3
GTEx Breast Mammary Tissue (Male) 1 0.084 2.0
GTEx Breast Mammary Tissue (Female) 6 0.365 2.2
GTEx Cells EBV-transformed lymphocytes 5 0.351 2.4
GTEx Cells Transformed fibroblasts 15 0.357 2.2
GTEx Colon Sigmoid 7 0.479 2.3
GTEx Colon Transverse 5 0.242 2.2
GTEx Esophagus Gastroesophageal Junction 9 0.623 2.4
GTEx Esophagus Mucosa 9 0.271 2.2
GTEx Esophagus Muscularis 17 0.526 2.3
GTEx Heart Atrial Appendage 7 0.443 2.3
GTEx Heart Left Ventricle 4 0.261 2.1
GTEx Liver 3 0.418 2.1
GTEx Lung 10 0.348 2.3
GTEx Muscle Skeletal 3 0.104 2.2
GTEx Nerve Tibial 9 0.208 2.2
GTEx Ovary 3 0.330 2.3
GTEx Pancreas 3 0.184 2.1
GTEx Pituitary 3 0.269 2.2
GTEx Prostate 4 0.479 2.4
GTEx Skin Not Sun Exposed Suprapubic 11 0.447 2.4
GTEx Skin Sun Exposed Lower leg 10 0.275 2.3
GTEx Small Intestine Terminal Ileum 2 0.434 2.4
GTEx Spleen 8 0.567 2.4
GTEx Stomach 4 0.275 2.3
GTEx Testis 5 0.158 2.2
GTEx Thyroid 16 0.400 2.2
GTEx Uterus 3 0.529 2.2
GTEx Vagina 2 0.315 2.3
GTEx Whole Blood 10 0.502 2.2
METSIM Adipose 6 0.130 2.0
NTR Blood 5 0.208 2.1
ROSMAP Brain Pre-frontal Cortex 15 0.342 2.2
YFS Blood 5 0.108 2.0
CommonMind Brain Pre-frontal Cortex 12 0.223 2.2
The Cancer Genome Atlas Bladder Urothelial Carcinoma 4 0.242 2.2
The Cancer Genome Atlas Breast Invasive Carcinoma 8 0.182 2.0
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 5 0.456 2.1
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 2.0
The Cancer Genome Atlas Esophageal Carcinoma 2 0.292 2.4
The Cancer Genome Atlas Glioblastoma Multiforme 3 0.294 2.1
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 11 0.404 2.2
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 14 0.342 2.1
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 6 0.293 2.0
The Cancer Genome Atlas Brain Lower Grade Glioma 16 0.372 2.1
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 3 0.271 1.9
The Cancer Genome Atlas Lung Adenocarcinoma 8 0.272 2.1
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 4 0.160 2.0
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 4 0.251 2.1
The Cancer Genome Atlas Pancreatic Adenocarcinoma 8 0.482 2.2
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 3 0.226 2.1
The Cancer Genome Atlas Prostate Adenocarcinoma 14 0.303 2.0
The Cancer Genome Atlas Rectum Adenocarcinoma 3 0.434 2.0
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.281 2.0
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 2.0
The Cancer Genome Atlas Stomach Adenocarcinoma 4 0.238 2.0
The Cancer Genome Atlas Testicular Germ Cell Tumors 5 0.391 2.1
The Cancer Genome Atlas Thyroid Carcinoma 14 0.271 2.1
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 1 0.197 2.1